Philippines' president accuses MNCs

20 July 2000

Multinational pharmaceutical companies have been accused by thePhilippines' President, Joseph Estrada, of lobbying and pressuring Trade Secretary Mar Roxas and Health Secretary Alberto Romualdez.

The two cabinet ministers, who are responsible for bringing down the cost of medicines, refused the offers, according to a story by Agence France Presse. Pres Estrada would not name the companies involved, it adds.

In February, the two ministers were asked to discuss with the multinational drug companies how to lower the cost of medicines, which Mr Estrada said were several times higher than in other Asian countries (Marketletters passim). At that time, the government also accused drug companies of ignoring and getting around a law requiring doctors to prescribe generic medicines rather than branded products, said the AFP, noting that the ministers have now agreed to import cheaper drugs made in India.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight